REFERENCES

APPENDIX

Table A1. FDA Approvals of Cancer Therapies From November 1, 2016 to October 31, 2017

<table>
<thead>
<tr>
<th>DRUG</th>
<th>INDICATION</th>
<th>APPROVAL DATE</th>
</tr>
</thead>
</table>

New approval

Rucaparib (Rubraca) For treatment of patients with deleterious BRCA mutation (germline and/or somatic)—associated advanced ovarian cancer who have treated with more than two chemotherapies. December 2016

Avelumab (Bavencio) For the treatment of patients <12 years of age with metastatic Merkel cell carcinoma. March 2017

Niraparib (Zejula) Maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. March 2017

Ribociclib (Kisqali) In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. March 2017

Brigadix (Alumbr) For treatment of patients with metastatic anaplastic lymphoma kinase—positive NSCLC who experienced disease progression on or who are intolerant to crizotinib. April 2017

Midostaurin (Pysdi) For treatment of patients with newly diagnosed AML who are FLT3 mutation—positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. April 2017

Dunbraka (Infirico) For treatment of patients with locally advanced or metastatic urothelial carcinoma who experience disease progression during or after platinum-containing chemotherapy or who experience disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. May 2017

Rituximab and hyaluronidase human (Rituxan Hyzcia) For adult patients with follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. June 2017

Neratinib (Nerlyn) For extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. July 2017

Daunorubicin and cytarabine ( Vyxoys) For treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, two types of AML that have a poor prognosis. August 2017

Enasidost (stitfra) For treatment of adult patients with relapsed or refractory AML with an asacitidine dehydrogenase-2 mutation as detected by an FDA-approved test. August 2017

Inotuzumab ozogamicin (Respinova) For treatment of adults with relapsed or refractory B-cell precursor ALL. August 2017

Tisag国际贸易 (Kynri） For treatment of patients <25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. August 2017

Avelumab (Venclexta) In combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy. September 2017

Benazitumab-avui (Mavib) Approved as a biosimilar to bevacizumab (Avastin). Bevacizumab-avui is the first biosimilar approved in the United States for the treatment of cancer. September 2017

Abbreviations: AML, acute myeloid leukemia; AHR, acute myeloid leukemia; EGR1, epidermal growth factor receptor; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1.


Shin G, Soboreno AF, Shields AF, et al Prospective pooled analysis of six phase III trials investigating duration of adjuvant (radio)osilabostin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC). The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 35, 2017 (suppl; abstr LBA1)


Eliasson B, Holm T, Pettersson D, et al Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). J Clin Oncol 35, 2017 (suppl; abstr LBA10004)


Brigatinib (Alunbrig) For the treatment of patients with ALK-rearranged NSCLC who have progressed on or are intolerant to crizotinib. December 2016

Ribociclib (Kisqali) For treatment of patients with metastatic anaplastic lymphoma kinase—positive NSCLC who experienced disease progression on or who are intolerant to crizotinib. April 2017

Midostaurin (Pysdi) For treatment of patients with newly diagnosed AML who are FLT3 mutation—positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. April 2017

Dunbraka (Infirico) For treatment of patients with locally advanced or metastatic urothelial carcinoma who experience disease progression during or after platinum-containing chemotherapy or who experience disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. May 2017

Rituximab and hyaluronidase human (Rituxan Hyzcia) For adult patients with follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. June 2017

Neratinib (Nerlyn) For extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. July 2017

Daunorubicin and cytarabine ( Vyxoys) For treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, two types of AML that have a poor prognosis. August 2017

Enasidost (stitfra) For treatment of adult patients with relapsed or refractory AML with an asacitidine dehydrogenase-2 mutation as detected by an FDA-approved test. August 2017

Inotuzumab ozogamicin (Respinova) For treatment of adults with relapsed or refractory B-cell precursor ALL. August 2017

Tisag国际贸易 (Kynri） For treatment of patients <25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. August 2017

Avelumab (Venclexta) In combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy. September 2017

Benazitumab-avui (Mavib) Approved as a biosimilar to bevacizumab (Avastin). Bevacizumab-avui is the first biosimilar approved in the United States for the treatment of cancer. September 2017

Abbreviations: AML, acute lymphoblastic leukemia; AML, acute myeloid leukemia; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1.